BACKGROUND: Negative results are frequent using anti-TNFalpha antibodies in sepsis models and clinical trials. METHODS AND RESULTS: Different prophylactic doses of anti-TNFalpha F(ab')2 antibody fragments were compared for the prevention of death by sepsis induced by cecal ligation and puncture (CLP) in mice. High (10 mg/kg) and very low (0.01 and 0.1 mg/kg) concentrations of anti-TNFalpha antibody fragments were not the most adequate for treating polymicrobial sepsis, since they did not significantly improve survival. To the contrary, intermediate doses (1 mg/kg) significantly protected the challenged animals. Protective activity was also observed when administration of the antibody fragments was initiated early (up to 30 min) after CLP. CONCLUSIONS: These results suggest that in processes where excessive production of cytokines is involved, the aim should be to return them to their physiologically acting range but not to inhibit their production. The timing of initiating therapy should also be considered in order to maximize the possible benefits.
BACKGROUND: Negative results are frequent using anti-TNFalpha antibodies in sepsis models and clinical trials. METHODS AND RESULTS: Different prophylactic doses of anti-TNFalpha F(ab')2 antibody fragments were compared for the prevention of death by sepsis induced by cecal ligation and puncture (CLP) in mice. High (10 mg/kg) and very low (0.01 and 0.1 mg/kg) concentrations of anti-TNFalpha antibody fragments were not the most adequate for treating polymicrobial sepsis, since they did not significantly improve survival. To the contrary, intermediate doses (1 mg/kg) significantly protected the challenged animals. Protective activity was also observed when administration of the antibody fragments was initiated early (up to 30 min) after CLP. CONCLUSIONS: These results suggest that in processes where excessive production of cytokines is involved, the aim should be to return them to their physiologically acting range but not to inhibit their production. The timing of initiating therapy should also be considered in order to maximize the possible benefits.
Authors: R Márquez-Velasco; A X Martínez-Velázquez; L M Amezcua-Guerra; F Flores-Guzmán; A Díaz-Quiñonez; F Massó; J Paniagua-Solís; R Bojalil Journal: Inflamm Res Date: 2011-07-02 Impact factor: 4.575
Authors: Matthias Lange; Csaba Szabo; Daniel L Traber; Eszter Horvath; Atsumori Hamahata; Yoshimitsu Nakano; Lillian D Traber; Robert A Cox; Frank C Schmalstieg; David N Herndon; Perenlei Enkhbaatar Journal: Shock Date: 2012-05 Impact factor: 3.454
Authors: Peter Newham; Daniel Ross; Peter Ceuppens; Shampa Das; James W T Yates; Catherine Betts; Jaimini Reens; Kevin J Randall; Richard Knight; Jennifer S McKay Journal: Inflamm Res Date: 2013-11-17 Impact factor: 4.575
Authors: Andreas von Knethen; Anne Schäfer; Laura Kuchler; Tilo Knape; Urs Christen; Edith Hintermann; Beate Fißlthaler; Katrin Schröder; Ralf P Brandes; Berit Genz; Kerstin Abshagen; Brigitte M Pützer; Lisa K Sha; Andreas Weigert; Shahzad N Syed; Martin Schulz; Ajay M Shah; Andreas Ernst; Mateusz Putyrski; Fabian Finkelmeier; Marina Pesic; Florian Greten; Michael Hogardt; Volkhard A J Kempf; Sandra Gunne; Michael J Parnham; Bernhard Brüne Journal: Theranostics Date: 2019-03-16 Impact factor: 11.556